AstraZeneca (LON:AZN) Earns Buy Rating from Analysts at Citigroup

Equities researchers at Citigroup assumed coverage on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a £170 price target on the biopharmaceutical company’s stock. Citigroup’s price objective would suggest a potential upside of 21.97% from the company’s current price.

Other equities analysts have also issued reports about the company. Jefferies Financial Group reiterated a “buy” rating and issued a £150 price objective on shares of AstraZeneca in a research note on Monday, November 10th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Thursday, January 15th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. Berenberg Bank raised their price objective on shares of AstraZeneca from £142 to £145 and gave the stock a “buy” rating in a research note on Tuesday, October 21st. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of AstraZeneca from £105 to £110 and gave the stock a “sell” rating in a research report on Thursday, January 15th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average target price of £143.33.

AstraZeneca Stock Up 1.4%

Shares of LON AZN traded up GBX 186 during mid-day trading on Tuesday, reaching £139.38. 37,735,145 shares of the company traded hands, compared to its average volume of 73,756,836. AstraZeneca has a fifty-two week low of GBX 9,573.51 and a fifty-two week high of £144.10. The company’s fifty day moving average is £137.63 and its two-hundred day moving average is £125.30. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. The stock has a market cap of £216.08 billion, a PE ratio of 23.15, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17.

Insider Buying and Selling at AstraZeneca

In other news, insider Nazneen Rahman sold 297 shares of AstraZeneca stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of £134.96, for a total value of £40,083.12. Insiders own 0.14% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.